Alexander Brinkmann

Dr. Alexander Brinkmann

Klinikum Heidenheim, Klinik für Anästhesie, operative Intensivmedizin und spezielle, Schmerztherapie, Heidenheim, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2019 in Infection
Verified
Journal Article
Open access
PDF file
Daniel RichterDaniel Richter
Daniel Richter
OFOtto Frey
Otto Frey
ARAnka Röhr
Anka Röhr
JRJason A. Roberts
Jason A. Roberts
AKAndreas Köberer
Andreas Köberer
ABAlexander Brinkmann
Alexander Brinkmann
Standard dosing and intermittent bolus application (IB) are important risk factors for pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in critically ill patients, particularly in those with sepsis and septic shock. We assessed the effect of therapeutic drug monitoring-guided (TDM), continuous infusion (CI) and individual dosing of piperacillin/tazobactam (PIP) on PK-target attainment in critically ill patients.

6 June 2019 in Trials
Verified
Journal Article
Open access
PDF file
OGon behalf of the TARGET Study Group
on behalf of the TARGET Study Group
SHStefan Hagel
Stefan Hagel
SFSandra Fiedler
Sandra Fiedler
AHAndreas Hohn
Andreas Hohn
ABAlexander Brinkmann
Alexander Brinkmann
Mathias W. PletzMathias W. Pletz
Mathias W. Pletz
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection with a hospital mortality in excess of 40%. Along with insufficient and delayed empirical antimicrobial therapy, inappropriate antimicrobial exposure has been identified to negatively affect patient outcomes. Receipt of prolonged infusion (i.e. extended or continuous infusion) of piperacillin/tazobactam (TZP) improves antimicrobial exposure and is associated with reduced mortality in patients with sepsis. Using therapeutic drug monitoring (TDM) with dosing tailored to the altered pharmacokinetics of the individual patient to avoid under- and overdosing may be a further strategy to improve patient outcomes. This current trial will address the question whether a TDM-guided therapy with TZP administered by continuous infusion will result in a greater resolution of organ dysfunction and hence better clinical outcome compared to continuous infusion of the total daily dose of TZP without TDM. The study is an investigator-initiated, multi-centre, parallel-group, single-blinded, randomised controlled trial. The trial will be conducted in several centres across Germany. Adult patients (aged ≥ 18 years) with severe sepsis or septic shock will be eligible for study participation. Participants will be randomly assigned to receive either TZP by continuous infusion guided by daily TDM of piperacillin (experimental group) or by continuous infusion without TDM guidance (total daily dose in normal renal function 13.5 g TZP) (control group). The pharmacokinetic (PK)/pharmacodynamic (PD) target will be 100% f T>4MIC (percentage of time during a dosing interval that the free [f] drug concentration exceeds 4 times the minimum inhibitory concentration). The primary efficacy endpoint is the change in mean total Sequential Organ Failure Assessment score from day 1 after randomisation until day 10 or discharge from the intensive care unit or death, whichever comes first. Secondary outcomes include mortality, clinical cure, microbiological cure, overall antibiotic use, individual components of the primary outcome, adverse events and analysis of PK and (PD) indices. This trial will assess for the first time whether continuous infusion of TZP guided by daily TDM in patients with sepsis will result in a greater resolution of organ dysfunction and hence better clinical outcome compared to continuous infusion without TDM. German Clinical Trials Register (GermanCTR), DRKS00011159 . Registered on 10 October 2016.

13 September 2016 in Medizinische Klinik - Intensivmedizin und Notfallmedizin
Verified
Journal Article
Closed access
PDF file
ABAlexander Brinkmann
Alexander Brinkmann
ARA. C. Röhr
A. C. Röhr
AKA. Köberer
A. Köberer
TFT. Fuchs
T. Fuchs
JPJ. Preisenberger
J. Preisenberger
OFO. R. Frey
O. R. Frey

3 June 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
UCUte Chiriac
Ute Chiriac
Daniel RichterDaniel Richter
Daniel Richter
OFOtto Frey
Otto Frey
ARAnka C. Röhr
Anka C. Röhr
SHSophia Helbig
Sophia Helbig
ABAlexander Brinkmann
Alexander Brinkmann
Optimization of antibiotic dosing is a treatment intervention that is likely to improve outcomes in severe infections. The aim of this retrospective study was to describe the therapeutic exposure of steady state piperacillin concentrations (cPIP) and clinical outcome in critically ill patients with sepsis or septic shock who received continuous infusion of piperacillin with dosing personalized through software-guided empiric dosing and therapeutic drug monitoring (TDM). Therapeutic drug exposure was defined as cPIP of 32–64 mg/L (2–4× the ‘MIC breakpoint’ of Pseudomonas aeruginosa). Of the 1544 patients screened, we included 179 patients (335 serum concentrations), of whom 89% achieved the minimum therapeutic exposure of >32 mg/L and 12% achieved potentially harmful cPIP > 96 mg/L within the first 48 h. Therapeutic exposure was achieved in 40% of the patients. Subsequent TDM-guided dose adjustments significantly enhanced therapeutic exposure to 65%, and significantly reduced cPIP > 96 mg/L to 5%. Mortality in patients with cPIP > 96 mg/L (13/21; 62%) (OR 5.257, 95% CI 1.867–14.802, p = 0.001) or 64–96 mg/L (30/76; 45%) (OR 2.696, 95% CI 1.301–5.586, p = 0.007) was significantly higher compared to patients with therapeutic exposure (17/72; 24%). Given the observed variability in critically ill patients, combining the application of dosing software and consecutive TDM increases therapeutic drug exposure of piperacillin in patients with sepsis and septic shock.

3 December 2018 in Der Anaesthesist
Verified
Journal Article
Closed access
PDF file
ABAlexander Brinkmann
Alexander Brinkmann
ARA. C. Röhr
A. C. Röhr
OFO. R. Frey
O. R. Frey
WKW. A. Krüger
W. A. Krüger
TBT. Brenner
T. Brenner
BGB. Grabein
B. Grabein

27 June 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
UCUte Chiriac
Ute Chiriac
Daniel RichterDaniel Richter
Daniel Richter
OFOtto Frey
Otto Frey
ARAnka C. Röhr
Anka C. Röhr
SHSophia Helbig
Sophia Helbig
ABAlexander Brinkmann
Alexander Brinkmann
Various studies have reported insufficient beta-lactam concentrations in critically ill patients. The optimal dosing strategy for beta-lactams in critically ill patients, particularly in septic patients, is an ongoing matter of discussion. This retrospective study aimed to evaluate the success of software-guided empiric meropenem dosing (CADDy, Calculator to Approximate Drug-Dosing in Dialysis) with subsequent routine meropenem measurements and expert clinical pharmacological interpretations. Adequate therapeutic drug exposure was defined as concentrations of 8–16 mg/L, whereas concentrations of 16–24 mg/L were defined as moderately high and concentrations >24 mg/L as potentially harmful. A total of 91 patients received meropenem as a continuous infusion (229 serum concentrations), of whom 60% achieved 8–16 mg/L, 23% achieved 16–24 mg/L, and 10% achieved unnecessarily high and potentially harmful meropenem concentrations >24 mg/L in the first 48 h using the dosing software. No patient showed concentrations 24 mg/L with TDM-guided dose adjustments. The combined use of dosing software and consecutive TDM promised a high rate of adequate therapeutic drug exposures of meropenem in patients with sepsis and septic shock.